t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy

Cancer
C Cameron YinDan Jones

Abstract

The t(3;21)(q26;q22) translocation is associated with myeloid leukemias and results in a chimeric oncoprotein containing AML1/RUNX1 variably fused to EAP, MDS1, and/or EVI1. The current study describes what to the authors' knowledge is the first large case series reported to date of 26 t(3;21)(q26;q22)-associated leukemias, in which 24 cases arose after chemotherapy. Conventional G-band karyotyping and flow cytometry immunophenotyping were performed. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect fusion transcripts between AML1 and EAP, MDS1, or EVI1, followed by DNA sequencing. In all 16 patients with chronic myeloproliferative disorders, including 14 with chronic myelogenous leukemia (CML), the occurrence of t(3;21) heralded myeloid blast transformation. Fifteen (93%) patients had been previously treated with hydroxyurea. Eight patients with chronic myeloproliferative disorders (CMPD) were found to have t(3;21) with t(9;22) as the sole cytogenetic abnormality; in 5 other patients this was accompanied by trisomy 8. Among 10 cases of t(3;21)-associated acute myeloid leukemia, 8 were secondary tumors after chemotherapy for other neoplasms that had been treated with regimens including fludarabine...Continue Reading

References

May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K MorishitaJ N Ihle
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·G NuciforaJ D Rowley
Jan 1, 1993·Leukemia & Lymphoma·F Mitelman
Feb 1, 1996·British Journal of Haematology·B JohanssonF Mitelman
Feb 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·S FearsG Nucifora
Jul 15, 1999·The New England Journal of Medicine·S FaderlH M Kantarjian
Jul 3, 2002·Nature Reviews. Cancer·Nancy A Speck, D Gary Gilliland
Nov 26, 2002·Seminars in Hematology·D Gary Gilliland
Dec 14, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Suyang HaoL Jeffrey Medeiros
Feb 8, 2003·Current Opinion in Genetics & Development·James R Downing
Jul 25, 2003·Biochemical and Biophysical Research Communications·Vitalyi SenyukGiuseppina Nucifora
May 25, 2004·Oncogene·Kinuko Mitani
Jul 24, 2004·Hematology/oncology Clinics of North America·Jorge Cortes, Michael E O'Dwyer
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Daniel HelblingThomas Pabst

❮ Previous
Next ❯

Citations

Jan 11, 2014·Current Hematologic Malignancy Reports·Paolo Neviani
Mar 6, 2009·Leukemia & Lymphoma·Peter Valent, Rotraud Wieser
Jul 18, 2015·American Journal of Clinical Pathology·Carlos E Bueso-RamosCurtis A Hanson
Aug 31, 2007·European Journal of Haematology. Supplementum·Gunnar Birgegård
Jul 16, 2010·International Journal of Laboratory Hematology·C C YinC E Bueso-Ramos
May 28, 2010·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Bee L Ng, Nigel P Carter
Mar 10, 2012·The Korean Journal of Internal Medicine·Hye Jeong ParkWoong-Soo Lee
May 19, 2007·European Journal of Haematology·Susan ShapiroMallika Sekhar
Aug 20, 2019·Expert Review of Hematology·Anette Lodvir HemsingHåkon Reikvam
Mar 21, 2019·Frontiers in Oncology·Ramachandran Krishna ChandranHariharan Sreedharan
Jun 19, 2007·Cancer Research·Vitalyi SenyukGiuseppina Nucifora
May 5, 2021·Leukemia & Lymphoma·Shady Adnan-AwadSatu Mustjoki

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.